Reactions
Heating Zn(CH3CO2)2 in a vacuum results in a loss of acetic anhydride, leaving a residue of "basic zinc acetate," with the formula Zn4O(CH3CO2)6. It can also be prepared by a reaction of glacial acetic acid with zinc oxide. The cluster compound has a tetrahedral structure with an oxide ligand at its center  Basic zinc acetate is a common precursor to metal-organic frameworks (MOFs). See also
Basic beryllium acetate - isostructural with basic zinc acetate


== References ==
Subsequently, cellular kinases catalyze the formation of ganciclovir diphosphate and ganciclovir triphosphate, which is present in 10-fold greater concentrations in CMV or herpes simplex virus (HSV)-infected cells than uninfected cells. Ganciclovir triphosphate is a competitive inhibitor of deoxyguanosine triphosphate (dGTP) incorporation into DNA and preferentially inhibits viral DNA polymerases more than cellular DNA polymerases. In addition, ganciclovir triphosphate serves as a poor substrate for chain elongation, thereby disrupting viral DNA synthesis by a second route. Pharmacokinetics
Absorption of the oral form is very limited—about 5% fasting, about 8% with food. It achieves a concentration in the central nervous system of about 50% of the plasma level. About 90% of plasma ganciclovir is eliminated unchanged in the urine, with a half-life of 2–6 hours, depending on renal function (elimination takes over 24 hours in end-stage renal disease). Administration
Acute infections are treated in two phases: 

induction phase, 5 mg per kilogram intravenously every 12 hours for 14–21 days, the intravenous dose given as a 1-hour infusion
maintenance phase, 5 mg per kg intravenously every dayStable disease is treated with 1000 mg orally three times daily. Similar dosing is used to prevent disease in high-risk patients, such as those infected with human immunodeficiency virus (HIV) or those with organ transplants. Ganciclovir is also available in slow-release formulations for insertion into the vitreous humour of the eye, as treatment for CMV retinitis (associated with HIV infection). A topical ophthalmic gel preparation of ganciclovir was recently approved for the treatment of acute herpes simplex keratitis. See also
Valganciclovir, the prodrug of ganciclovir

References
Further reading
External links
"Ganciclovir".